About us


PVP is a private venture capital firm based in Berlin, investing in early-stage healthcare companies across Europe with a focus on medical device, digital health and platform technology companies.
Peppermint VenturePartners was established in 2008 by Ingeborg Neumann, Dr. Joachim Rautter and Dr. Klaus Stöckemann. As experts in healthcare, we pool more than 40 years of experience in the healthcare and venture capital industry.

We are driven by an entrepreneurial spirit to help motivated founders to achieve the full potential of their innovative ideas. We not only provide financial backing but also experience, know-how and a broad industry network in order to successfully bring novel healthcare products and services to the market.


As a dedicated partner, we guide all the important phases of company development, from the inception of a company through all phases of financing up to a strategic exit.
If a company has an outstanding idea, but does not yet have an established and experienced team, we are happy to assist in assembling and completing the required management team.



We are focusing on investments in early stage medical device, diagnostics and digital health, as well as platform technology companies.
Target companies should address an “unmet medical need” and having developed a patent-protected technology and/or product or a new business model. A fundamental criterion for an investment by us is that the entrepreneurs have their sights set on tackling previously unsolved medical problems with the aim of improving diagnosis and therapies of diseases and at the same time increase quality of life and positively impacting on cost containment.

Our Partnerships

In addition to managing the CBF, in 2011 PVP took over responsibility for the external management of the newly established Helmholtz Validation Fund (HVF) on behalf of the Helmholtz Association.
Within the scope of this collaboration, PVP gained superb access to the largest research association in Germany.

Our Current Funds

At the end of 2010 PVP launched the Peppermint Charité Biomedical Fund (CBF) in collaboration with the Charité Foundation.
Within the scope of a partnership with the Charité – Universitätsmedizin Berlin, we have access to a unique network in healthcare, thanks to the outstanding expertise of one of Europe’s largest and most renowned University hospital, along with its international partners.


Since May 2011, CBF has taken an equity position in a total of seven companies and built up a highly promising portfolio in its target areas.
PVP plans to complete up to four additional investments out of the CBF until end of 2016.


Our team has many years of experience in building early-stage healthcare companies.

The combination of complementary skill sets and interdisciplinary technical expertise, in conjunction with a comprehensive national and international network in the healthcare sector, enables PVP to guide all of a company’s key stages of development, from start-up, and financing rounds through growth stages and strategic exits. Since the year 2000, PVP team members have been working in various constellations on various deals and exits.




Dr. Joachim Rautter

Dr. Joachim Rautter

Dr. Klaus Stöckemann

Dr. Klaus Stöckemann

Managing Partner View Details
Dr. Magnus Holm

Dr. Magnus Holm

Venture Partner View Details
Dr. Markus Müschenich

Dr. Markus Müschenich

Venture Partner View Details


Henriette Braun

Henriette Braun

Dr. Lea Bogner

Dr. Lea Bogner

Project Manager View Details



Ingeborg Neumann is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of Peppermint Charité Biomedical Fund.

In 1997, she established the Peppermint Holding GmbH – a medium-sized industrial group based in Berlin. The Peppermint Group develops and produces high-end, innovative textiles for the fields of fashion, home textiles and technical textiles, with a staff of more than 750 employees, achieving worldwide sales of approx. EUR 90 million.
In addition, Neumann started up the first Peppermint Venture Capital Fund in the year 2000.

What’s more, Ingeborg Neumann serves on several supervisory boards and advisory committees; e.g. German Textile + Fashion Confederation (President), in the Federation of German industries (Vice President and Treasurer), in the Berlin water utility company (member of the Supervisory Board), in the association Friends of the National Gallery of Berlin (Member of the Management Board).

Ingeborg Neumann studied business economics in Münster and Munich. She has a degree in business and the German title of “Diplom-Kauffrau”.

Dr. Joachim Rautter

Dr. Joachim Rautter


“We ask a lot of our companies, but we are always fair in our dealings with them.”

Joachim Rautter is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of Peppermint Charité Biomedical Fund.

Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund. He has over 15 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH and CellAct Pharma GmbH, and also serves on the Board of CAP-CMV GmbH, CryoTherapeutics GmbH and Labfolder GmbH.

Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies, e.g. at BioTOP Berlin-Brandenburg and the innovation concept of the German state of Brandenburg.

Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.

Dr. Klaus Stöckemann

Dr. Klaus Stöckemann

Managing Partner

“When funding innovative ideas, you have to be bold enough to take the first step, even alone, and swim against the flow.”

Klaus Stöckemann is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of Peppermint Charité Biomedical Fund.

Prior to the launch of Peppermint VenturePartners, he was a general partner in the international healthcare venture team of 3i plc. During the time at 3i he was responsible for more than 12 investments. His track record at 3i included not only IPOs of companies such as Epigenomics, Jerini and Santhera, but also the trade sales of Evotec Neuroscience, Amaxa and Elbion.

Prior to his tenure at 3i, Stöckemann held leading positions in research as well as in business development at major pharma corporations such Schering AG and ASTA Medica (a Degussa-Hüls group subsidiary).

Klaus Stöckemann was a member of the supervisory boards or boards of Combinature, Epigenomics, Jerini, Amaxa, Immatics, as well as IntelliDx and Zonare in the United States. He is currently the Chairman of the boards of Humedics GmbH, Emperra GmbH, Caterna Vision, and is a board member of Implandata Ophthalmic Products GmbH.

Stöckemann’s more than 14-year experience in the venture capital industry makes him an experienced venture capital investor.

He has a Ph.D in biology and pharmacology from the University of Mainz, as well as an MBA from WHU/Kellogg, Northwestern University in the United States.

Dr. Magnus Holm

Dr. Magnus Holm

Venture Partner

Magnus Holm has been fortifying Peppermint’s investment team as a venture partner since September 2012.

Holm has many years of operative experience in various executive positions in the medical technology industry. In addition to the development and clinical approval of medical products, his duties have also included business development, along with sales and marketing.

As General Manager for companies such as Biosense Webster, EMEA or Stereotaxis Inc. (USA), Holm made a decisive contribution towards the introduction of new, innovative products and technologies that quickly established themselves in clinical routines in the field of cardiology and electro-physiology (3-D electro-anatomical mapping of heart chambers, drug eluting stents and robot controls of interventional therapeutic heart catheters).

Besides his role as Venture Partner at PVP, Holm is the CEO of SWAT Medical AS, a cardiology focused early stage medial device company in Sweden and serves as a board member for Personal MedSystems GmbH in Germany.

Magnus Holm has a Master of Science in Biomedical Technology and a PhD in Medical Technology from the University of Lund (Sweden).

Dr. Markus Müschenich

Dr. Markus Müschenich

Venture Partner

Dr. Markus Müschenich is a specialist for Pediatrics and Adolescent Medicine, in addition to having a Master’s degree in Public Health (MPH). Since 2014, he has been a venture partner of PVP, and supports the PVP team as an expert for Digital Health in the evaluation and mentoring of early-stage companies.

Up to 2012, he was a member of the Management Board of the Sana Kliniken AG hospital group in Ismaning and previously a member of the Medical Management Board of the faith-based healthcare provider, Paul Gerhardt Diakonie, in Berlin. Since 2012, he has been a member of the Management Board of the German Association of Internet Medicine. As the founder of the think tank ConceptHealth, he is specialized in strategic foresight for medicine of the future.

In addition, Müschenich is Managing Partner and Co-Founder of FLYING HEALTH – the start-up factory. FLYING HEALTH assists health start-ups with an Internet medicine focus in their strategic development, company building and market entry.




Simone Schöpp joined Peppermint VenturePartners in January 2015. She supports our portfolio companies with her experiences in controlling and in the healthcare sector.

Prior to Peppermint she worked as Senior Financial Analyst with a pharmaceutical Contract Research Organisation first in Berlin and later in the US. Simone holds a Diploma in Business Administration from the HTW in Berlin.

Before and during her studies she gained professional experience in the research and in the finance department of an innovative biotech start-up, giving her a comprehensive understanding of the industry.

Henriette Braun

Henriette Braun


Henriette Braun has been working as the Assistant to the Managing Directors of PVP since December 2012.

Previously, she worked for several years as an executive assistant in the logistics field and as a scientific project team member in an environmental engineering firm.

Braun has a degree in business with a specialization in the fields of Environmental Management and Management of Small to Medium-Size Enterprises (SMEs).

Dr. Lea Bogner

Dr. Lea Bogner

Project Manager

Lea Bogner is working as a project manager for Peppermint VenturePartners since May 2016. During her PhD at the Department of Physics of the Freie Universität Berlin and at the Fritz Haber Institute of the Max-Planck Society she was engaged in elementary electronic processes in organic solar cells and LEDs.
Prior to this Lea Bogner graduated in chemistry from the Freie Universität Berlin.


Expert Panel

The investment team is supported by established experts from research and industry. They assist PVP in the international benchmarking of investment opportunities and help new portfolio companies by providing strategic consulting, serving on advisory boards or in management.


Insurance and Health Care Expert

Albert is Managing Director at “Meine-Gesundheit-Services GmbH”, a company offering secure e-portals and apps managing interactions between patients, doctors / clinics and private health insurers in a fully digital way. The offerings facilitate billing and administrative processes for privately insured patients and provide a wide range of mobile health services such as medication services, electronic patient records and diagnosis-related coachings.

Before that he held different positions at AXA Krankenversicherung AG.  Albert was Head of Health Strategy from  2012 to 2016, responsible for expanding and further developing the health insurance business and for exploring new business areas. From 2010 to 2012 Albert headed the “Aktiver Gesundheitsservice” [active health service] department for chronic and seriously ill policy holders and was responsible for developing and expanding care programmes. At the health insurance companies AXA/DBV-Winterthur he was project leader from 2007 to 2010 in the area of integration and data migration.

After studying theoretical physics at the University of Bonn and subsequently receiving a doctorate in mathematical physics, Albert worked from 2001 to 2007 as a management consultant at Boston Consulting Group, with a special focus in the area of insurance.

Prof. Dr. Maurice Buchbinder

Expert for Cardiovascular Diseases
Buchbinder studied medicine at the McGill University in Montreal, Canada. After completing his studies, he specialized at Stanford University in the treatment of cardiovascular diseases, and accomplished groundbreaking work in the new field of interventional cardiology.

Dr. Buchbinder played an integral role in the development of many medical products that are used routinely today in the practice of interventional medicine.

For many years, his interest has been dedicated to the improvement of treatment of patients with diseases of the coronary arteries. In the recent past, Buchbinder launched a series of innovations involving the use of percutaneous treatment of various illnesses of the heart valves, as a replacement of invasive surgical open-heart procedures.

Dr. Buchbinder is the co-founder of several successful companies, including the portfolio company CryoTherapeutics. He assists PVP with his clinical expertise and his knowledge in the area of medical start-ups in interventional cardiology.

Prof. Dr. Carl Erb

Expert for Ophthalmology

Erb studied medicine at the Ruhr-Universität Bochum, Freie Universität Berlin and at the Royal Preston Hospital, England.

From 2005 to 2011, he was head physician in the ophthalmology department at the Schlosspark-Klinik Berlin. Since 2006, Erb has also been a special guest professor at the Charité Berlin.

Since 2002, he has been actively involved in the German Ophthalmology Society, where he has also served as Vice-President of the section on glaucoma since 2010.

Since 2011, Erb has been working at the eye clinic at Wittenbergplatz in Berlin as a specialist for cataract and glaucoma surgery.

Dr. Wolfgang Götz

Expert for Minimal-Invasive Technologies
Götz is a heart surgeon with over 10 years of clinical experience. His main area of interest is in the development of minimal-invasive technologies for the replacement of heart valves. He is the founder and Managing Director of Transcatheter Technologies GmbH in Regensburg, a company developing a new trans-catheter aorta valve.


Expert for Paediatrics and Endocrinology
In 1980, Grüters-Kieslich completed her medical studies at the Freie Universität Berlin and obtained her PhD in 1982. After beginning her residency in pediatrics, between 1982 and 1984 she worked on a DFG research fellowship in the field of perinatology at the University of California, Los Angeles. In 1998, she was appointed to a C3 professorship for pediatric endocrinology in the Medical Department of the Humboldt University of Berlin, and in 2004, she was appointed to a C4 chair for pediatric endocrinology.

Since 2005, she has been Medical Director of the Charité Gynecology, Perinatal, Pediatric and Adolescent Medicine with Perinatal Center and Human Genetics. Grüters-Kieslich’s main area of research is in the field of molecular pathogenesis of thyroid diseases and the pathophysiology of juvenile obesity.


Expert for Medical Devices in Ophthalmology
Christine Kreiner studied pharmaceutical chemistry at the Ludwig‐Maximilians‐Universität in Munich and subsequently worked for several years as an assistant professor, and later as the research director of a pharmaceutical firm. In 1985, she launched her own company and has since founded and managed three firms in the healthcare field.

These companies were involved in the development, production, and worldwide sales of pharmaceuticals and medical products in the segments of ophthalmology and aesthetics. She led the first two companies, Adatomed and AcriTec, to revenues of more than EUR 20 million, and successfully sold them to Chiron (Adatomed) and Carl Zeiss (AcriTec).

In the year 2007, she established S&V Technologies in Hennigsdorf and BSC Medical Devices in Munich, in order to develop new biomaterials in the field of aesthetics and ophthalmology.
Kreiner is a member of several international medical societies and actively involved as a research consultant for various companies, along with the German state of Brandenburg. In addition, Kreiner has developed numerous patents.

 Dr. Fred Schaebsdau

Diagnostic Expert

Schaebsdau studied medicine at the University of Gießen and during his specialist training performed longer periods of residency in the urological departments at the University of Chicago, the Medical University of Hannover and the University of Freiburg. He is also licensed to practice medicine in the United States and Germany. While at the Medical University of Hannover, he conducted laboratory research projects funded by the German Research Foundation, earning his doctorate. In the year 1993, Schaebsdau earned his MBA from The Wharton School of the University of Pennsylvania.

He began his career at Eli Lilly Medical Devices Division (later Guidant) Cardiac Rhythm Management as Head of Sales & Marketing in Germany. Afterwards, he worked as Manager at The Mac Group (later Gemini Consulting), a strategy consultancy in Munich. Schaebsdau subsequently switched to Booz Allen Hamilton and led the global strategy projects in the pharmaceutical, medical technology and health-care industry.

For a group of investors, he established the BioScience Ventures Group, a venture capital company with a focus on “early stage” investments in the German biotechnology industry, and became its Managing Director. In the year 2004, Schaebsdau joined Abbott Diagnostics, where he held an executive position with increasing responsibility, both in the EMEA region and later in the global organisation of Abbott Diabetes Care. From 2009 to August 2015, Schaebsdau was Head of Global Strategy and Business Development at Roche Diabetes Care.

Mark Wächter

Mobile Strategy Expert

Mark Wächter is marketer with many years professional and leadership experience in the areas of Consumer Goods, Internet and Mobile Communications. In May 2005 he founded MWC.mobi, a worldwide active management consultancy focusing on Mobile Strategy Development and served clients in over 30 countries on all continents in the past years.

Mark is head of the Mobile Marketing Association (MMA) in Germany (locally known as BVDW Section Mobile) and member of MMAs Board of Directors. He is co-founder of MobileMonday and chairs the advisory board of Germany’s first Master Degree Program in Mobile Marketing at Leipzig School of Media. Mark is a Mobile Aficionado since the very beginning and became a globally well respected Mobile Media Evangelist and Strategist aka ‚Mr. Mobile‘, acting as advisor and mentor on many Mobile Initiatives.

In December 2015 Springer Gabler published his book ‚MOBILE STRATEGY‘. This has been chosen as basic compendium for the charismha study on Mobile Health Apps. Connected Health is a core competency of Mark. He organizes the world’s largest Medical Mobile Solutions award, the annual MEDICA App Competition. In May 2016 he co-initiated the global thinktank on Digital Health, FTR4H.


Advisory Board

The PVP Advisory Board supports the team as a discussion partner on questions regarding the strategic development of the portfolio. It consists of experienced managers in the healthcare field, clinical experts and successful companies.

Dr. Rolf Zettl
Johannes Schneider Littfeld
Dr. Bernd Wegener


Caterna Vision GmbH
CEVEC Pharmaceuticals GmbH
CryoTherapeutics GmbH
EMPERRA GmbH E-Health Technologies
Humedics GmbH
Implandata Ophthalmic Products GmbH
Miracor Medical Systems GmbH
labfolder GmbH

The Peppermint Charité Biomedical Fund (CBF)

The Peppermint Charité Biomedical Fund (CBF-1) is an independent venture capital fund that was launched in November 2010.

Within the scope of cooperation with Charité – Universitätsmedizin Berlin, the CBF has privileged access to the network of the Charité and the international partners of the University Hospital. This cooperation is simultaneously harnessed for the evaluation of all investment opportunities. In association with PVP’s established network, encompassing additional first-rate medical research institutions, venture capital firms, as well as companies, high-caliber investment opportunities can be identified.
The CBF invests in start-ups and early-stage companies in the healthcare sector. These companies should already be able to demonstrate an initial “proof of concept” for their technology, their product or their business model. Investments are geared mainly towards early-stage medical devices as well as digital health companies addressing medical problems and markets with high growth potential. In addition, selective investments are also made in attractive pharma projects, e.g. platforms.  


In addition to our own activities in fund management, we work very closely with other private and public venture funds, new instruments of validation funding, as well as with technology transfer agencies of the key German research foundation and universities. Currently, the most significant areas of collaboration for Peppermint VenturePartners include the Charité – Universitätsmedizin Berlin, the Charité Foundation and Helmholtz Association.

With the establishment of the Helmholtz Validation Fund (HVF) in the year 2011, the Helmholtz Association introduced a new financial instrument across several institutions, tapping funding from the Initiative and Networking Fund. The aim of the HVF is to close the existing gap between research findings and their marketable applications, as well as public research and private institutions. The funding levels from the Helmholtz Validation Fund range between 0.25 and 1 million euros per year. The idea is to evaluate new technologies in terms of their technical feasibility and to achieve a functioning prototype or initial positive pre-clinical validation. In order to ensure professional guidance according to industry and venture capital standards, a network of industry experts and project managers assists the team.

Peppermint VenturePartners has taken over the external fund management as an experienced early-stage investor.




Press Reviews




UPDATE – PVP Newsletter

The PVP team regularly publishes the so-called Update, the company newsletter, where trends and topics from the healthcare industry, entrepreneurs and new portfolio companies are introduced.


  UPDATE Nr. 1 | Main focus: m-health

  UPDATE Nr. 2 | Main focus: eye diseases

  UPDATE Nr. 3 | Main focus: smart labs

  PORTFOLIO NEWS | The Journey from MedTech into Digital Health (October 2017)

Ihr Name / Your name (*)

Ihre E-Mail-Adresse / your email (*)



Contact form

Your name (required)

Your email (required)

Your message


Peppermint VenturePartners GmbH

Neues Kranzler Eck
Kurfürstendamm 21
10719 Berlin
T: +49 30 59 00 64- 412
F: +49 30 59 00 64- 401



Intern (m/f)

We are regularly seeking student interns.

Your profile:

Your main course of studies should be one of the following: Chemistry, physics, medicine, biology, engineering or business. It is an advantage if you can already demonstrate experience based on internships, e.g. in the fields of innovation management and project assessment, project analysis and project controlling. Good skills in Office applications are a prerequisite.


Strong analytical skills are desired, as the nature of the work can be highly complex. As a small team, we expect a team-oriented work ethic, dependability, strong communication skills and self-initiative. Written and verbal fluency in German and English are a prerequisite.

IYour tasks:

  • Support in the maintenance of the deal flow database
  • Support in the due diligence process. This involves: Market and competitor analyses, references, interviews and written summaries of findings.
If you are interested, please contact:

Dr. Klaus Stöckemann

Tel. +49 30 590064 412

Peppermint VenturePartners GmbH
Kurfürstendamm 21
10719 Berlin, Germany

Email to Henriette Braun:




Peppermint VenturePartners GmbH
Sitz der Gesellschaft: Berlin
Registergericht: Berlin-Charlottenburg HRB 117003B
Finanzamt für Körperschaften I
Ust-Id-Nr. DE 263663009

Inhaltlich Verantwortlicher gemäß § 6 MDStV:

Ingeborg Neumann, Dr. Joachim Rautter, Dr. Klaus Stöckemann

Legal notice

Welcome to our website. If you continue to browse and use this website you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern [business name]’s relationship with you in relation to this website.

The term ‘Peppermint VenturePartners GmbH’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is Neues Kranzler Eck, Kurfürstendamm 21, 10719 Berlin. The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:
The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trade marks reproduced in this website which are not the property of, or licensed to, the operator are acknowledged on the website.

Unauthorised use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).


CEVEC and CellGenix cooperation leads to expansion of CellGenix cytokine portfolio with CAP®Go technology-derived TGF-ß1 for ex vivo cell culture

This portfolio expansion is the result of an ongoing collaboration and license agreement between CEVEC and CellGenix for the development and GMP production of selected cytokines for ex vivo cell culture therapy applications using CEVEC’s proprietary CAP®Go technology CEVEC’s CAP®Go technology enables CellGenix access to new cytokines and proteins

Read More

CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference

Newly developed helper-free AAV packaging cell line provides unique solution for large-scale viral gene therapy vector production Easy and stable production processes, independent of transient transfection or helper virus Data from CEVEC’s successful proof-of-concept studies will be presented at the conference Cologne CEVEC Pharmaceuticals GmbH (CEVEC), the expert in

Read More

Miracor Medical raises € 25m

Funds will be used to support clinical and prepare commercial activities. Company relocates from Austria to Belgium Awans, Belgium and Vienna, Austria Miracor Medical Systems GmbH (Miracor Austria) and Miracor Medical SA (Miracor Medical) today announced the closing of € 25m as part of a Series D financing round. The

Read More

CEVEC has been granted a new CAP®Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach

New patent paves the way for further market expansion for CAP®Go expression platform Patent strengthens CEVEC’s unique position in producing recombinant proteins with tailor-made glycosylation Important milestone in establishing CAP®Go as the production standard for difficult-to- express recombinant glycoproteins Cologne, Germany CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the

Read More

labfolder selected for the Merck Accelerator

The Berlin start-up company labfolder, which is developing an electronic lab notebook, was selected out of 475 applicants worldwide to participate in the Accelerator program of the science and technology company Merck in Darmstadt for three months, starting today. Berlin and Darmstadt. Over the next three months, the Berlin startup

Read More

labfolder Expands to North America and Initiates Collaboration with the German Accelerator Life Sciences

Digital lab notebook platform company opens office in Cambridge to support U.S. growth and customer Relations BERLIN & CAMBRIDGE, Mass. labfolder and the German Accelerator Life Sciences (GALS), an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), today announced the initiation of an extensive collaboration supporting

Read More

Peppermint VC realizes lucrative exit…

Berlin Peppermint VC realizes lucrative exit through the acquisition of next-generation chemotherapy agent CAP7.1 from German biotech CellAct by Mundipharma CellAct Pharma GmbH together with the Mundipharma global network has announced a new deal for the development and commercialization of smart chemotherapy (CAP7.1) with a total deal value exceeding 250

Read More

Appointment of Bent Johnsen as CEO for EMPERRA®

Potsdam EMPERRA®, specializing in digital health solutions for people living with diabetes, has appointed Mr. Bent Johnsen as Managing Director and CEO.  Mr. Johnsen, a Danish national, has an extensive international career in the health care sector and has lived and worked in multiple countries within Europe and the USA. 

Read More

Tackling the German Healthcare System

What are the latest trends in biotech and digital health funding and why is Germany still using fax machines in healthcare? a podcast by Tjasa Zajc with Klaus Stoeckemann, Managing Partner Part 1 Part 2

Read More

Emperra Wins the 2017 Game Changers Award for Digital Business Models

Potsdam Emperra GmbH, a start-up company based in Potsdam, Germany, has received the Finance Monthly’s 2017 Game Changers Award. The award is honouring Emperra for its new digital business models, which - based on innovative hardware - enable business revenue to be generated from digital solutions. The 2017 Game Changers

Read More

CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production

Parties intend to jointly enable AAV production in CEVEC's CAP(R)GT cells in combination with PlasmidFactory's broad AAV serotype plasmid portfolio Collaboration will significantly increase the value of CAP(R)GT for CEVEC customers by broadening the spectrum of available adeno-associated viral (AAV) vectors for gene therapy applications Cologne. CEVEC Pharmaceuticals GmbH

Read More

Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO

Reinforcement of senior management team to leverage growth phase of Humedics Berlin. The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de

Read More

Biotech platform: Interview with CEVEC pharmaceuticals

The CSO of PVPs Portfolio Company CEVEC pharmaceuticals, Nicole Faust, was interviewed by labbiotech.eu - the leading digital media covering the European biotech industry - on CEVECS CAP Technology and it's fight against the Zika Virus. Read more:

Read More

CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections

Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development Cologne. CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with

Read More

Emperra Wins Prestigious Award With Innovative Diabetes Device

London. Emperra GmbH E-Health Technologies was announced Business Worldwide Magazine's (BWM) 2016 Company of the Year Award/Medical Device Industry Europe for its innovative diabetes management system. The device, known as ESYSTA® combines modern hardware (a blood glucose meter and insulin pen) with intelligent software in order to allow data to

Read More